[Federal Register Volume 65, Number 248 (Tuesday, December 26, 2000)]
[Notices]
[Page 81533]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 00-32815]



[[Page 81533]]

-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The inventions listed below are owned by agencies of the U.S. 
Government and are available for licensing in the U.S. in accordance 
with 35 U.S.C. 207 to achieve expeditious commercialization of results 
of federally-funded research and development. Foreign patent 
applications are filed on selected inventions to extend market coverage 
for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent 
applications listed below may be obtained by writing to the indicated 
licensing contact at the Office of Technology Transfer, National 
Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, 
Maryland 20852-3804; telephone: 301/496-7057; fax: 301/402-0220. A 
signed Confidential Disclosure Agreement will be required to receive 
copies of the patent applications.

Vibrio cholerae O139 Conjugate Vaccines

    Shousun Szu, Zuzana Kossaczka, John Robbins (NICHD)
    DHHS Reference No. E-274-00/1; PCT/US00/24119 filed 01 Sep 2000
    Licensing Contact: Peter Soukas; 301/496-7056 ext. 268; e-mail: 
[email protected]
    Cholera remains an important public health problem. Epidemic 
cholera is caused by two Vibrio cholerae serotypes O1 and O139. The 
disease is spread through contaminated water. According to information 
reported to the World Health Organization in 1999, nearly 8,500 people 
died and another 223,000 were sickened with cholera worldwide. This 
invention is a polysaccharide-protein conjugate vaccine to prevent and 
treat infection by Vibrio cholerae O139 comprising the capsular 
polysaccharide (CPS) of V. cholerae O139 conjugated through a 
dicarboxylic acid dihydrazide linker to a mutant diphtheria toxin 
carrier. In addition to the conjugation methods, also claimed in the 
invention are methods of immunization against V. cholerae O139 using 
the conjugates of the invention. The inventors have shown that the 
conjugates of the invention elicited in mice high levels of serum 
antibodies to CPS, a surface antigen of Vibrio cholerae O139, that have 
vibriocidal activity. Clinical trials of the two most immunogenic 
conjugates have been planned by the inventors. This invention is 
further described in Infection and Immunity 68(9), 5037-5043, Sept. 
2000.

Inhibition of MXR Transport by Acridine Derivatives

    Susan Bates, Robert Robey (NCI)
    DHHS Reference No. E-258-99/0 filed 20 Jan 2000
    Licensing Contact: Vasant Gandhi; 301/496-7056 ext. 224; e-mail: 
[email protected]
    The invention relates to a new use for a compound, an acridine 
derivative, as an inhibitor of multidrug resistance in cancer cells. 
Specifically, the inventors have shown that the compound modulates the 
transport of compounds from mitoxantrone-resistant (MXR) cells wherein 
the cells overexpress an MXR gene. The MXR gene is also known by the 
following designations: BCRP, ABCP, and ABCG2.

Jack Spiegel,
Director, Division of Technology, Development and Transfer, Office of 
Technology Transfer, National Institutes of Health.
[FR Doc. 00-32815 Filed 12-22-00; 8:45 am]
BILLING CODE 4140-01-P